(1) The year ended December 31, 2023 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards ...
(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...
This morning, I am joined by Christopher Scott Hill, Core's Chief Financial Officer, and Gwendolyn Y. Gresham, Core's Senior Vice President and Head of Investor Relations. Gwen will start by making ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The HonorHealth Research ...
(2) Includes the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. (3) Includes gain on insurance ...
probability of performance condition for certain executive's share awards. (2) Three months ended June 30, 2025 and September 30, 2025 includes the write-down of inventory. (3) Three months ended June ...
due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized ...
HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results